Hoofd Menu

The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study

Bron: The Lancet - Crude and fully adjusted ORs of psychotic disorders for the combined measure of frequency plus type of cannabis use in the whole sample

The Lancet - Published: March 19, 2019 - The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study - Cannabis use is associated with increased risk of later psychotic disorder but whether it affects incidence of the disorder remains unclear. The reseachers aimed to identify patterns of cannabis use with the strongest effect on odds of psychotic disorder across Europe and explore whether differences in such patterns contribute to variations in the incidence rates of psychotic disorder. 

Marta Di Forti, PhD - Diego Quattrone, MD -Tom P Freeman, PhD - Giada Tripoli, MSc - Charlotte Gayer-Anderson, PhD - Harriet Quigley, MD - Victoria Rodriguez, MD - Hannah E Jongsma, PhD - Laura Ferraro, PhD - Caterina La Cascia, PhD - Prof Daniele La Barbera, MD - Ilaria Tarricone, PhD - Prof Domenico Berardi, MD - Prof Andrei Szöke, PhD - Prof Celso Arango, PhD - Andrea Tortelli, PhD - Eva Velthorst, PhD - Prof Miguel Bernardo, PhD - Cristina Marta Del-Ben, PhD - Prof Paulo Rossi Menezes, PhD - Prof Jean-Paul Selten, PhD - Prof Peter B Jones, PhD - James B Kirkbride, PhD - Prof Bart PF Rutten, PhD - Prof Lieuwe de Haan, PhD - Prof Pak C Sham, PhD - Prof Jim van Os, PhD - Prof Cathryn M Lewis, PhD - Prof Michael Lynskey, PhD - Prof Craig Morgan, PhD - Prof Robin M Murray, FRS